ROLE OF METABOLIC DYSFUNCTION IN ADVANCED PROSTATE CANCER
RESEARCHER PROFILE
Dr Jennifer Gunter (Filmed March 2024)
Senior Research Associate (Cancer Metabolism),
Australia Prostate Cancer Research Centre – Queensland (APCRC-Q) & Group Leader, Cancer Metabolism Group,
Translational Research Institute (TRI),
Queensland, Australia
Dr Jennifer (Jenni) Gunter is a mid-career researcher, with a metabolic research background spanning almost 15 years. She leads a research team examining the metabolic plasticity of cancer cells with the aim of identifying therapeutic targeting strategies that extend patient survival. Jenni completed her PhD in 2005 at the Oxford Centre for Diabetes, Endocrinology and Metabolism at Oxford University.
She returned to Australia in 2006 with a University of Queensland Postdoctoral Fellowship at the UQ Diamantina Institute to pursue studies into the turnover and metabolism of adipocytes in obesity.
In 2010, Jenni joined the Institute of Health and Biomedical Innovation, at QUT to research the intersection between chronic metabolic disorders and their emerging relationship to cancer. These studies were focused on the role of insulin and the relationship between the insulin and androgen signalling axes.
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
-
De-prescribing medications in older adults with dementia
Dr. Daniel Hoyle is a Senior Lecturer in Therapeutics and Pharmacy Practice at the School of Pharmacy and Pharmacology, University of Tasmania. He is also an experienced clinical pharmacist with expertise in medication management in older people. Dr. Hoyle’s research interests focus on improving medicine use in older people with dementia.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Unnecessary tests and treatments in low value critical care
Dr Gerben Keijzers is a Senior Staff Specialist Emergency Physician at the Gold Coast University Hospital Emergency Department. His research focus includes low-value care, which is in the area of unnecessary tests and treatments with minimal benefits. Dr Keijzers has contributed to over 100 publications and more than 20 grant applications. Through his involvement in multi-site collaborative research projects, he encourages critical thinking and curiosity among clinical staff, striving to enhance both patient care and the efficiency of healthcare resources.
